Vigil Neuroscience, Inc. is a Commercial Services company based in the United States of America focused on developing therapies for neurodegenerative diseases by targeting microglia. They are dedicated to improving patient's lives by utilizing modern neuroscience drug development techniques. With a Risk Rating Score of 22.4, the company is classified as having a Medium Risk assessment. Their lead clinical candidate, iluzanebart, is currently in Phase 2 of a PoC trial for ALSP patients. Additionally, they are working on VG-3927, a small molecule TREM2 agonist for common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. is committed to ESG principles in their approach to healthcare innovation.